Proactiveinvestors United Kingdom Cello Health PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Cello Health PLC RSS feed en Thu, 20 Jun 2019 10:12:30 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190610094152_14104621/ Mon, 10 Jun 2019 09:41:52 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190610094152_14104621/ <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190524124505_14087196/ Fri, 24 May 2019 12:45:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190524124505_14087196/ <![CDATA[RNS press release - Issue of Equity ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190520162930_14080681/ Mon, 20 May 2019 16:29:30 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190520162930_14080681/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190515070020_14074090/ Wed, 15 May 2019 07:00:20 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190515070020_14074090/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190508133001_14066797/ Wed, 08 May 2019 13:30:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190508133001_14066797/ <![CDATA[News - Cello Health expects 'robust' profits growth in first half ]]> https://www.proactiveinvestors.co.uk/companies/news/219849/cello-health-expects--robust--profits-growth-in-first-half-219849.html Healthcare-focused consultancy Cello Health PLC (LON:CLL) is confident its second quarter will continue the “very good” start made to 2019.

Growth in like-for-like net revenue and headline profit before tax in the first quarter was described as “good” in a statement issued ahead of the AIM-listed company’s annual shareholder meeting.

The consulting businesses and the US operations put in an “excellent” performance and are expected to continue this trend in the second quarter.

Last year the company changed its name to Cello Health to reflect the new ongoing strategic focus on the healthcare sector, where it services 24 of the top 25 pharmaceutical clients globally as well as a wide range of biotech and medical equipment outfits.

Without mentioning numbers, Cello’s confidence about the second quarter led management to expect headline PBT growth for the first half of the year will be “robust”. Last year, headline PBT increased 6.4% to £12.2mln on revenue up 2.3% to £104.8mln.

Cash conversion has been better than expected, continuing the trend from last year, which finished with £6.3mln in the coffers. Management plan to put some of this cash to use through acquisitions and are assessing suitable growth opportunities in the US.

Chairman Chris Jones was quoted as saying that the year to date has been as expectated and that the board is confident of achieving a successful full year result in 2019, "in line with expectations".

]]>
Wed, 08 May 2019 07:31:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219849/cello-health-expects--robust--profits-growth-in-first-half-219849.html
<![CDATA[RNS press release - AGM Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190508070002_14065603/ Wed, 08 May 2019 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190508070002_14065603/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190501121502_14059535/ Wed, 01 May 2019 12:15:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190501121502_14059535/ <![CDATA[RNS press release - Annual Report and Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190415111207_14041247/ Mon, 15 Apr 2019 11:12:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190415111207_14041247/ <![CDATA[Media files - Cello Health Plc - Elevator Pitch ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12966/cello-health-plc---elevator-pitch-12966.html Thu, 11 Apr 2019 13:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/12966/cello-health-plc---elevator-pitch-12966.html <![CDATA[RNS press release - Capital Markets Event ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190410070002_14035109/ Wed, 10 Apr 2019 07:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190410070002_14035109/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190404100002_14028939/ Thu, 04 Apr 2019 10:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190404100002_14028939/ <![CDATA[News - finnCap sets 145p price target on Cello Health shares in wake of recent ‘good’ full-year 2018 results ]]> https://www.proactiveinvestors.co.uk/companies/news/217351/finncap-sets-145p-price-target-on-cello-health-shares-in-wake-of-recent-good-full-year-2018-results-217351.html finnCap has set a target price of 145p per share on Cello Health PLC (LON:CLL) in the wake of the global healthcare-focused advisory group’s recent full-year results.

In a note to clients, analysts at the ‘house’ broker said: “Cello reported a good set of FY 2018 results with net fees +2%, PBT +6%, EPS +14% (aided by lower tax), DPS +10% and net cash £6.3m up from £1.6m last year.”

READ: Cello is confident of a strong performance in 2019

They pointed out that Cello’s 2017 acquisitions continued to perform well and the Health division broadened and deepened its client offering once again.

Looking forward, the analysts added, the focus will remain on growing the group’s presence in the US and leveraging Signal’s digital capability into the healthcare sector.

They concluded: “We reiterate our view that the market backdrop for Cello’s technically based, strategic advisory services is strong and defensive, supporting good growth prospects.”

In late afternoon trading, Cello Health shares were changing hands at 124.50p each, up 0.4% on Tuesday’s close.

]]>
Wed, 27 Mar 2019 15:56:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217351/finncap-sets-145p-price-target-on-cello-health-shares-in-wake-of-recent-good-full-year-2018-results-217351.html
<![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190327130001_14018050/ Wed, 27 Mar 2019 13:00:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190327130001_14018050/ <![CDATA[News - Cello Health off to a strong start in 2019 ]]> https://www.proactiveinvestors.co.uk/companies/news/217048/cello-health-off-to-a-strong-start-in-2019-217048.html  

What it does

Cello Health PLC (LON:CLL) calls itself a healthcare-focused advisory group.

It has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

And Signal, which provides “digital, social media and branding expertise” to companies.

This division used to be focused sectors such as technology and retail, but it has taken a much greater interest in health of late.

Cello’s big claim to fame is that it works with 24 of the top 25 pharmaceutical companies around the world.

 

How it’s doing

Cello has kicked off its new year in strong fashion, with good levels of forward bookings and a number of new business wins already secured.

Given the hot start, management recently said it was confident of a strong performance in 2019, in line with what the market expects.

As for 2018, the company reported headline profit before tax of £12.2mln, up 6.4% from the £11.4mln reported for 2017.

Statutory profit before tax rose 44.7% to £8.4mln from £5.8mln the year before, on the back of a 2.3% increase in net revenue to £104.8mln from 2017's £102.5mln.

Overall, headline operating profit growth was underpinned by a strong divisional performance from Cello Health. The firm had already flagged that Signal suffered a dip in the top-line, partially reflecting tougher trading conditions in the UK.

The group enjoyed strong cash flows in the second half of the year and ended 2018 with net funds of £6.3mln, up from £1.6mln a year earlier.

The full-year dividend was bumped up by 10% to 3.85p from 3.50p the previous year, marking the 13th year in a row that the payout has been increased.

 

What the boss says

“2018 marked an important moment in Cello's development as we changed our name to Cello Health plc to reflect our ongoing strategic focus and developed our Board to support that strategy,” said chief executive Mark Scott.

“It is pleasing to see strong earnings per share growth and we have accordingly increased our dividend for the thirteenth successive year.

“We now intend to build on this momentum to support Cello Health's position as a leading healthcare focused advisory group globally.”

 

What analysts say

“Cello has reported a good set of FY 2018 results with PBT +6%, EPS +14% (aided by lower tax), DPS +10% and net cash £6.3m up from £1.6m last year,” said finnCap analyst Guy Hewett at the time of the recent results release.

“2017 acquisitions have continued to perform well and the Health division continues to broaden and deepen the client offering.

“Looking forward, the focus will remain on growing the group’s presence in the US and leveraging Signal’s digital capability into the healthcare sector.

“We do not anticipate making any major changes to our forecasts (apart from improved net cash and higher dividend), and reiterate our view that the market backdrop for Cello’s technically based, strategic marketing services is strong and defensive, supporting good growth prospects.”

]]>
Fri, 22 Mar 2019 05:30:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/217048/cello-health-off-to-a-strong-start-in-2019-217048.html
<![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190321151048_14011323/ Thu, 21 Mar 2019 15:10:48 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190321151048_14011323/ <![CDATA[Media files - Cello Health Plc makes strong start to 2019 with good order book and new wins ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/12675/cello-health-plc-makes-strong-start-to-2019-with-good-order-book-and-new-wins-12675.html Thu, 21 Mar 2019 11:33:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/12675/cello-health-plc-makes-strong-start-to-2019-with-good-order-book-and-new-wins-12675.html <![CDATA[News - Cello is confident of a strong performance in 2019 ]]> https://www.proactiveinvestors.co.uk/companies/news/216916/cello-is-confident-of-a-strong-performance-in-2019-216916.html Cello Health PLC (LON:CLL) has begun 2019 with good levels of forward bookings and has already landed a number of new business wins.

The board of the global healthcare-focused advisory group is confident of a strong performance in 2019, in line with the current market expectations.

WATCH: Cello Health Plc makes strong start to 2019 with good order book and new wins

In its results statement covering 2018, the company reported headline profit before tax of £12.2mln, up 6.4% from the £11.4mln reported for 2017.

Statutory profit before tax rose 44.7% to £8.4mln from £5.8mln the year before, on the back of a 2.3% increase in net revenue to £104.8mln from 2017's £102.5mln.

Overall, headline operating profit growth was underpinned by a strong divisional performance from Cello Health, with net revenue up 4.3% on a constant currency (CC) like-for-like (LFL) basis while headline operating profit margins improved to 18.5% from 17.7%.

The company had already flagged that Signal, which provides digital, social media and branding expertise to companies, suffered a dip in the top-line, partially reflecting tougher trading conditions in the UK in the markets Signal serves; Cello Signal's constant currency like-for-like net revenue declined by 2.9% and headline operating margins eased to 9.4% from 9.5% in 2017.

The group enjoyed strong cash flows in the second half of the year and ended 2018 with net funds of £6.3mln, up from £1.6mln a year earlier.

The full-year dividend has been bumped up by 10% to 3.85p from 3.50p the previous year, marking the 13th year in a row that the payout has been increased.

Our results are out https://t.co/y8Ici6RzJM strong performance and continued delivery of consistent results.

— CelloHealthplc (@CelloHealthplc) March 21, 2019

"2018 marked an important moment in Cello's development as we changed our name to Cello Health PLC to reflect our ongoing strategic focus and developed our board to support that strategy,” said Mark Scott, the chief executive of Cello.

“We now intend to build on this momentum to support Cello Health's position as a leading healthcare-focused advisory group globally,” he added.

In a note to clients, analysts at ‘house’ broker finnCap said: “We do not anticipate making any major changes to our forecasts (apart from improved net cash and higher dividend), and reiterate our view that the market backdrop for Cello’s technically based, strategic marketing services is strong and defensive, supporting good growth prospects.”

finnCap has a 145p price target on Cello Health shares, which in afternoon trading were changing hands at 122p each, down 1.2% on Wednesday’s close, with the stock up 10% in the year-to-date.

 -- Adds analyst comment, updates share price --

]]>
Thu, 21 Mar 2019 08:24:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216916/cello-is-confident-of-a-strong-performance-in-2019-216916.html
<![CDATA[RNS press release - Preliminary Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190321070009_14009974/ Thu, 21 Mar 2019 07:00:09 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190321070009_14009974/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190306135135_13992669/ Wed, 06 Mar 2019 13:51:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190306135135_13992669/ <![CDATA[RNS press release - Notice of Full Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190207070006_13961100/ Thu, 07 Feb 2019 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190207070006_13961100/ <![CDATA[Media files - Cello Health Plc expects to hit expectations for 2018 after 'excellent year' ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11918/cello-health-plc-expects-to-hit-expectations-for-2018-after--excellent-year--11918.html Mon, 21 Jan 2019 10:49:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11918/cello-health-plc-expects-to-hit-expectations-for-2018-after--excellent-year--11918.html <![CDATA[News - Cello Health on track and buoyed by strength of pharma consultancy ]]> https://www.proactiveinvestors.co.uk/companies/news/212759/cello-health-on-track-and-buoyed-by-strength-of-pharma-consultancy-212759.html Cello Health plc (LON:CLL) expects to hit expectations for 2018 after an “excellent year” at its big pharma consultancy division.

Strong like-for-like growth in this arm, known as health, offset a slower outcome from brand and marketing operation Signal.

WATCH: Cello Health Plc expects to hit expectations for 2018 after 'excellent year'

The health division also saw good like-for-like gross profit growth and better-operating margins.

Operating profit performance was good in all three core capabilities consulting, insight and communications, said the statement.

"Contributions from the businesses acquired in 2017 continue to be in line with the board's expectations, extending the reach of Cello Health into the biotech community to complement the pharmaceutical core of the business and increasing the focus on the US market."

Signal’s slower year reflected lower activity by some UK-based clients.

Full year results will include £1.2mln of start-up costs for the launch of social media analytics tool Pulsar in the US and the new Boston office of Cello Health. Restructuring Signal’s capacity in Cheltenham has also cost £300,000.

Pulsar US will be consolidated into the group’s results in 2019.

 

]]>
Thu, 17 Jan 2019 08:05:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212759/cello-health-on-track-and-buoyed-by-strength-of-pharma-consultancy-212759.html
<![CDATA[RNS press release - Pre-Close Trading Statement ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190117070003_13937296/ Thu, 17 Jan 2019 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20190117070003_13937296/ <![CDATA[RNS press release - Block Listing Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181214092434_13904187/ Fri, 14 Dec 2018 09:24:34 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181214092434_13904187/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181123154504_13879065/ Fri, 23 Nov 2018 15:45:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181123154504_13879065/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181119144504_13872285/ Mon, 19 Nov 2018 14:45:04 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181119144504_13872285/ <![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181112113003_13863517/ Mon, 12 Nov 2018 11:30:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181112113003_13863517/ <![CDATA[News - Cello Health promotes non-exec director Chris Jones as long-time chairman steps down ]]> https://www.proactiveinvestors.co.uk/companies/news/208536/cello-health-promotes-non-exec-director-chris-jones-as-long-time-chairman-steps-down-208536.html Healthcare-focused advisory group Cello Health PLC (LON:CLL) has appointed non-executive director Chris Jones as its new chairman with immediate effect.

Jones has sat on the Cello board for two years and will take over the reins from long-time chairman Allan Rich, who has stepped down.

READ: Cello Health sees half-year profits climb almost 10%

The change was first announced in last month’s half-year results, when it reported a 9% rise in profits.

“The board wishes to wholeheartedly thank Allan Rich for his invaluable contribution to Cello over the years from its inception,” said chief executive Mark Scott.

“Chris knows the group and the healthcare industry well and can help guide the board through the group's next stage of growth and development.”

Jones was previously the chairman and chief executive of marketing group J Walter Thompson, which is owned by ad giant WPP PLC (LON:WPP).

Shares were down 0.9% to 114p in mid-afternoon trading on Monday.

]]>
Mon, 05 Nov 2018 14:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208536/cello-health-promotes-non-exec-director-chris-jones-as-long-time-chairman-steps-down-208536.html
<![CDATA[RNS press release - Directorate Change ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181105140006_13855402/ Mon, 05 Nov 2018 14:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181105140006_13855402/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181031153001_13850028/ Wed, 31 Oct 2018 15:30:01 +0000 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181031153001_13850028/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181010070005_13822568/ Wed, 10 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181010070005_13822568/ <![CDATA[RNS press release - Appointment of Executive Director ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181002070011_13812214/ Tue, 02 Oct 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20181002070011_13812214/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180925130001_13803960/ Tue, 25 Sep 2018 13:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180925130001_13803960/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180925070023_13802915/ Tue, 25 Sep 2018 07:00:23 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180925070023_13802915/ <![CDATA[RNS press release - Transfer of FTSE classification to Healthcare ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180924113945_13801936/ Mon, 24 Sep 2018 11:39:45 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180924113945_13801936/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180921101502_13800035/ Fri, 21 Sep 2018 10:15:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180921101502_13800035/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180920160002_13798990/ Thu, 20 Sep 2018 16:00:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180920160002_13798990/ <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180920070017_13797557/ Thu, 20 Sep 2018 07:00:17 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180920070017_13797557/ <![CDATA[Media files - Cello Health 'making good headway' with decent organic growth ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/10527/cello-health-making-good-headway-with-decent-organic-growth-10527.html Wed, 19 Sep 2018 14:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/10527/cello-health-making-good-headway-with-decent-organic-growth-10527.html <![CDATA[News - Cello Health sees half-year profits climb almost 10% ]]> https://www.proactiveinvestors.co.uk/companies/news/205210/cello-health-sees-half-year-profits-climb-almost-10-205210.html Healthcare-focused advisory group Cello Health PLC (LON:CLL) has reported a rise in half-year profits, driven by another six months of strong growth from its Cello Health division.

The company has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

READ: Cello makes strong start to the year

And Signal, which provides “digital, social media and branding expertise” to companies. This division used to be focused sectors such as technology and retail, but it has taken a much greater interest in health of late.

Cello’s claim to fame is that it works with 24 of the top 25 pharmaceutical companies around the world.

Operating profits in the Health business climbed 16.1%, while they edged 3.9% higher in the Signal division, driven by improved margins.

Overall, group revenue was broadly flat at £78.5mln in the six months ended June 30, while pre-tax profits jumped 9.3% to £5.1mln (H1 17: £4.6mln).

Cello has been expanding across the pond over the past year or so and the US now accounts for almost half of its profit. The US businesses it acquired last year as part of this drive continue to perform well, the company said.

Given the strong bottom-line performance, Cello has raised its dividend by 5% to 1.1op (H1 17: 1.05p).

Chairman stepping down

“Cello Health is successfully building its early stage asset development advisory platform for biotech clients, as well as growing its core later stage and post-launch franchise with pharmaceutical clients,” said chief executive Mark Scott.

“The depth and breadth of client relationships held by Cello Health under Master Service Agreements (MSAs) is impressive, underpinning revenue visibility.

“The leadership team is actively engaged with increasing the size of the global service platform, including Signal's communications capabilities. Signal, and particularly Pulsar, is rapidly building its healthcare franchise.

“The vision of developing Cello Health into a leading global advisor to healthcare and related clients is taking shape.”

Within the announcement, long-term chairman Allan Rich announced he is to retire from the board of directors. He will be replaced by current non-executive Chris Jones.

Shares were up 1.5% to 135p shortly before market close in London.

-- Updates for video link and share price --

]]>
Wed, 19 Sep 2018 09:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205210/cello-health-sees-half-year-profits-climb-almost-10-205210.html
<![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180919070004_13795804/ Wed, 19 Sep 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180919070004_13795804/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180822135117_13764898/ Wed, 22 Aug 2018 13:51:17 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180822135117_13764898/ <![CDATA[RNS press release - Notification of Half Year Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180817070003_13758925/ Fri, 17 Aug 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180817070003_13758925/ <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180816140001_13758393/ Thu, 16 Aug 2018 14:00:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180816140001_13758393/ <![CDATA[RNS press release - Board Changes ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180816133001_13758370/ Thu, 16 Aug 2018 13:30:01 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180816133001_13758370/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180723070007_13726727/ Mon, 23 Jul 2018 07:00:07 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180723070007_13726727/ <![CDATA[News - Cello Health makes strong start to the year; in track to meet expectations ]]> https://www.proactiveinvestors.co.uk/companies/news/201116/cello-health-makes-strong-start-to-the-year-in-track-to-meet-expectations-201116.html Cello Health plc (LON:CLL) said trading in the first six months of the year had been strong, adding it expects results for the year to be in line with market forecasts.

The healthcare-focused advisory group said it saw “good growth” in revenues and earnings, while profit margins were slightly higher than the comparable period last year.

READ: Cello Health confident of "achieving a successful result in 2018" after strong start to year

The Cello Health division had a “robust” first-half, with "excellent" like-for-like gross profit growth, investors were told.

Cello Signal was described as having had a “solid” start to the year. The company said while gross profit had declined slightly year-on-year, but margins have increased, meaning operating profits will expand slightly.

The businesses acquired last year are now fully absorbed into Cello and “continue to make a good contribution”, the company said.

]]>
Thu, 19 Jul 2018 07:33:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201116/cello-health-makes-strong-start-to-the-year-in-track-to-meet-expectations-201116.html
<![CDATA[RNS press release - Pre-close Trading Update ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180719070003_13723282/ Thu, 19 Jul 2018 07:00:03 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180719070003_13723282/ <![CDATA[RNS press release - Change of registered office ]]> https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180717070009_13719883/ Tue, 17 Jul 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/187/LSE20180717070009_13719883/